MedTrace Logo

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

NCT02111096 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2019-10-09

Study results available
· View outcomes & findings →

Summary

The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician. The study treatment is expected to last 12 months (52 weeks).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

LY2409021

Administered orally

DRUG

Sitagliptin

Administered orally

DRUG

Placebo

Administered orally

DRUG

Metformin

Administered orally

DRUG

Sulfonylurea

Administered orally

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States
  • Greece
  • Puerto Rico
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02111096 on ClinicalTrials.gov